All In Biotech

Drug Trial Radar · NCT07057765

Predictive Value of CRP, Albumin, CAR, and mGPS in Treatment Outcomes of DLBCL

Predictive Value of CRP, Albumin, CAR, and mGPS in DLBCL: A Prospective Cohort Study on Treatment Outcomes and Toxicity

Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

40

Planned (sponsor's estimate)

Start

May 5, 2025

Primary completion

Nov 2027

Study completion Dec 2027

Sponsor

Lead sponsor
Ain Shams UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jul 10, 2025

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This observational study evaluates the predictive value of systemic inflammatory markers-CRP, albumin, CRP-to-albumin ratio (CAR), and modified Glasgow Prognostic Score (mGPS)-in patients with diffuse large B-cell lymphoma (DLBCL) receiving R-CHOP chemotherapy. The study examines associations with treatment response, toxicity, and clinical characteristics.

Conditions

  • DLBCL - Diffuse Large B Cell Lymphoma
  • Markers of Inflammation

Interventions

  • Observational Assessment of Standard R-CHOP TreatmentDrug

    Patients will receive R-CHOP chemotherapy (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) as part of routine clinical care. The study does not assign or modify treatment. Data will be collected to assess the association between inflammatory markers and clinical outcomes.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate (ORR) Following 3 Cycles of R-CHOP Based on Baseline Inflammatory MarkersTime frame: Baseline (Day 1 of Cycle 1) and Day 63 (End of Cycle 3; each cycle is 21 days)
  2. Incidence of Treatment-Related Toxicity During Initial Treatment According to Baseline Inflammatory MarkersTime frame: Day 1 of Cycle 1 through Day 63 (End of Cycle 3; each cycle is 21 days)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Clinical Oncology and Nuclear Medicine Department, Faculty of Medicine, Ain Shams University

    Cairo, Cairo Governorate, Egypt · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.